Biomedical subjects

A R Belous

Publications and source records attributed to A R Belous.

3 recordsLinked to original sources

PubMed1999

[The status of serotonin protein -- a serotonin transporter in thrombocytes in patients with somatoform disorders].

The role of serotonin transporter (SERT) protein in the development of somatoform disorders (SD) was investigated. An association study was performed in terms of the evaluation of the level of SERT immunoreactive (IR-SERT) protein using site-specific antibodies directed at SERT C-terminus fragment, poorly conserved among the other cotransporters. The level of the anxious symptomatology was also estimated in the patients with SD. 22 patients, who met DSM-IV criteria for somatoform disorders, and 32 normals were examined. In platelets from normals, IR-SERT protein migrated as a difuse band between 68 and 105 kDa, and a major sharper band at 43 kDa. Almost complete disappearance of platelet 43 kDa IR-SERT protein band was observed in most of the patients with SD. These findings permitted to suggest a possibility of either biosynthetic or processing abnormality of SERTs in the affected population, that might reflect a dysfunction of serotonin neurotransmission in CNS of the patients with SD.

Adult↗

PubMedDate not supplied

The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders.

The role of the serotonin transporter protein (STP) in the development of somatoform [corrected] disorders was addressed in a correlational study of the levels of immunoreactive STP (IR-STP) using site-specific antibodies against the least conserved (among a group of other cotransporters) epitope at the C-terminal of STP and the level of anxiety symptoms in patients with somatoform [corrected] disorders. A total of 22 patients were studied, with DSM-IV diagnoses of somatoform [corrected] disorders, along with 32 mentally healthy subjects of comparable age and sex. Immunoblotting of IR-STP from patients from healthy donors produced a diffuse band between 68 and 105 kDal and a clear narrow band at 43 kDal. The 43-kDal IR-STP protein was almost completely absent from most patients, as compared with the levels of this protein in healthy donors. This result suggests an abnormality of STP processing or, perhaps, alternative splicing of the gene encoding STP in patients with somatoform [corrected] disorders, and this appears to reflect the dysfunction in serotoninergic transmission in the CNS in these patients.

Adult↗

PubMedDate not supplied

[Decrease in the platelet level of 43 kDa immunoreactive fraction of serotonin transporting protein correlates with depressive symptoms in patients with somatoform disorders].

To elucidate the role of serotonin transporter (SERT) protein as a candidate target for somatoform disorders (SD), we have performed an association study of the SERT immunoreactive (IR-SERT) protein level by using site-specific antibodies directed at C-terminus epitope poorly conserved among other cotransporters. 22 patients who met DSM-IY criteria for SD and 32 healthy volunteers matched in sex and age participated in the study. In platelets from all healthy donors, IR-SERT proteins migrates as a diffuse band between 75 and 102 kDa and a major sharper band at 43 kDa. We revealed almost complete disappearance of platelet 43 kDa IR-SERT protein in all patients with SD. All patients were rated with Hamilton Depressive Rating Scale (HDRS). There were found a significant negative correlation between residual IR-SERT 43 kDa protein level and HDRS Scores [r = -0.83; P < 0.000001]. These findings suggest that a biosynthetic or processing abnormality may exist in SERTs in the affected population and may reflect the dysfunction of serotonin neurotransmission in CNS.

Adult↗